Breakingviews - AstraZeneca’s messaging warrants a review, too
LONDON (Reuters Breakingviews) - AstraZeneca’s vaccine home run is in danger of turning into a curveball. The $134 billion drug giant is planning to review its Covid-19 vaccine candidate to clarify how effective it is. While it’s doing so, the UK group should probably do a separate review of how it communicates.
